We give you a written timeline estimate for your case before you commit.Ask about treatment
Chronic inflammatory demyelinating polyneuropathy (CIDP): US-approved treatments and how families in the Gulf can access them
A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
CIDP: the short answer
The US FDA has approved two medicines covered on this page for CIDP, each for a specific group of patients: Vyvgart Hytrulo and Hyqvia. On 17 October 2026, two of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Vyvgart Hytrulo and Hyqvia.
- Gulf registers (checked 17 October 2026): see each medicine below.
- Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is CIDP?
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder in which there is inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering of the nerve fibers, called the myelin sheath.[1]
Loss of myelin slows or blocks nerve signals and causes weakness, paralysis or problems with movement, especially of the arms and legs. Sensory problems may also occur. Symptoms usually affect both sides of the body, and some people have a slow steady course while others have symptoms that stabilize and then relapse.[1]
CIDP is sometimes thought of as the chronic form of the most common type of Guillain-Barre syndrome. Its prevalence is estimated at around 5 to 7 cases per 100,000 people.[1]
CIDP in the Gulf
A 2025 case report from Saudi Arabia described leprosy neuropathy misdiagnosed as CIDP, a reminder that careful diagnosis matters.[2]
We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 2 of 2 were listed in Saudi Arabia and 2 of 2 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[3, 4]
US FDA-approved medicines for CIDP
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)
US FDA-approved for adults with CIDP, and adults with generalized myasthenia gravis. Vyvgart Hytrulo is an injection under the skin.[5]
Current US label version: 15 July 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[3, 4]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Hyqvia (immune globulin infusion 10% with recombinant human hyaluronidase)
US FDA-approved for maintenance therapy in adults with CIDP, and primary immunodeficiency. It is an immune globulin given under the skin.[6]
Current US label version: 18 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[3, 4]
How families in the Gulf can access treatment
If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[7, 8] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
- Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for CIDP
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for CIDP?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Vyvgart Hytrulo and Hyqvia. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Vyvgart Hytrulo available in Saudi Arabia or the UAE?
We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.
How can a family in the Gulf get Vyvgart Hytrulo?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Does Reserve Meds diagnose or prescribe?
No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.
How is CIDP different from Guillain-Barre syndrome?
Guillain-Barre syndrome usually develops over about 3 to 4 weeks and then improves, while CIDP is long-lasting and may relapse. Most people with CIDP cannot name an infection before it started.
Sources for the condition-specific answers: [1]
Sources
Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.
- NORD (National Organization for Rare Disorders): Chronic Inflammatory Demyelinating Polyneuropathy
- AlOtaibi MK, et al. Unmasking the mimic: Leprosy neuropathy misdiagnosed as chronic inflammatory demyelinating polyneuropathy: A case report from Saudi Arabia. Neurosciences (Riyadh). 2025 (PubMed 40199529)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed: VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) US prescribing information, label version 15 July 2026
- DailyMed: HYQVIA (immune globulin infusion 10% with recombinant human hyaluronidase) US prescribing information, label version 18 June 2026
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Guillain-Barre syndrome
- Multiple sclerosis
- Vyvgart Hytrulo: drug overview
- Named-patient access in the Gulf, explained
- US-approved medicines not yet registered in the Gulf
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
This page is general health information, not medical advice. It does not replace a consultation with your doctor.